Corneal neovascularization (NV) is a major cause of blindness worldwide. Our research objective is to identify the role of membrane type 1 matrix metalloproteinase (MT1-MMP) activity and its proteolytic functions in corneal NV. Our laboratory has found that per cellular MT1-MMP activates proMMP-2, degrades collagen, and results in vascular endothelial growth factor (VEGF) upregulation in corneal stromal fibroblasts. We also have demonstrated that fibroblast growth factor-2 (FGF-2) upregulates MT1-MMP and that MT1-MMP and FGF-2 have a synergistic effect on VEGF upregulation in stromal fibroblasts. We performed additional experiments showing that exosomes derived from cultured stromal fibroblasts are rich in active MT1-MMP. We hypothesize that FGF-2 upregulation of MT1-MMP in stromal fibroblasts results in membrane-associated activity localized at the leading edge of migrating stromal fibroblasts. We further hypothesize that stromal fibroblast-associated active MT1-MMP promotes corneal neovascularization through two potential mechanisms: (i) upregulation of VEGF by synergistic activity with FGF-2/FGFR1 and (ii) breakdown of the extracellular matrix by stromal fibroblast-tethered or exosome-tethered MT1-MMP. The proposed research will test various aspects of our hypotheses:
Aim A) determine the spatio-temporal localization of MT1-MMP enzymatic activity in vivo and in response to FGF-2/FGFR1 activation;
Aim B) determine the necessity of MT1- MMP enzymatic activity on MT1-MMP-induced upregulation of VEGF in stromal fibroblasts;and, Aim C) examine the enzymatic activity of stromal fibroblast membrane- and exosome-associated MT1-MMP on collagen degradation and angiogenesis. Characterization of the spatial and temporal relationships of MT1- MMP activity in corneal angiogenesis and evaluation of the two proposed mechanisms of corneal NV will be valuable for identifying potential targets for therapeutic intervention in the treatment of corneal NV.
MT1-MMP enzymatic activity plays an important role in corneal revascularization. Transcriptional up regulation of VEGF and pericellular/transcellular ECM degradation may be two distinct mechanisms by which enzymatically active MT1-MMP promotes angiogenesis.
|Zhong, Wei; Montana, Mario; Santosa, Samuel M et al. (2018) Angiogenesis and lymphangiogenesis in corneal transplantation-A review. Surv Ophthalmol 63:453-479|
|Yamakawa, Michael; Doh, Susan J; Santosa, Samuel M et al. (2018) Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 38:1769-1798|
|Zhong, Wei; Gao, Xinbo; Wang, Shuangyong et al. (2017) Prox1-GFP/Flt1-DsRed transgenic mice: an animal model for simultaneous live imaging of angiogenesis and lymphangiogenesis. Angiogenesis 20:581-598|
|Giri, Pushpanjali; Azar, Dimitri T (2017) Risk profiles of ectasia after keratorefractive surgery. Curr Opin Ophthalmol 28:337-342|
|Han, Kyu-Yeon; Tran, Jennifer A; Chang, Jin-Hong et al. (2017) Potential role of corneal epithelial cell-derived exosomes in corneal wound healing and neovascularization. Sci Rep 7:40548|
|Chang, Jin-Hong; Putra, Ilham; Huang, Yu-Hui et al. (2016) Limited versus total epithelial debridement ocular surface injury: Live fluorescence imaging of hemangiogenesis and lymphangiogenesis in Prox1-GFP/Flk1::Myr-mCherry mice. Biochim Biophys Acta 1860:2148-56|
|Han, Kyu-Yeon; Chang, Jin-Hong; Lee, Hyun et al. (2016) Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci 57:3313-22|
|Yang, Jessica F; Walia, Amit; Huang, Yu-hui et al. (2016) Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions. Surv Ophthalmol 61:272-96|
|Han, Kyu-Yeon; Chang, Michael; Ying, Hong-Yu et al. (2015) Selective Binding of Endostatin Peptide 4 to Recombinant VEGF Receptor 3 In Vitro. Protein Pept Lett 22:1025-30|
|Han, Kyu-Yeon; Dugas-Ford, Jennifer; Lee, Hyun et al. (2015) MMP14 Cleavage of VEGFR1 in the Cornea Leads to a VEGF-Trap Antiangiogenic Effect. Invest Ophthalmol Vis Sci 56:5450-6|
Showing the most recent 10 out of 37 publications